- Home
- JMM vs CTSO Comparison
JMM vs CTSO Comparison
Compare JMM & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JMM
- CTSO
- Stock Information
- Founded
- JMM 1988
- CTSO 1997
- Country
- JMM United States
- CTSO United States
- Employees
- JMM N/A
- CTSO N/A
- Industry
- JMM Trusts Except Educational Religious and Charitable
- CTSO Medical/Dental Instruments
- Sector
- JMM Finance
- CTSO Health Care
- Exchange
- JMM Nasdaq
- CTSO Nasdaq
- Market Cap
- JMM 56.8M
- CTSO 51.6M
- IPO Year
- JMM N/A
- CTSO N/A
- Fundamental
- Price
- JMM $5.98
- CTSO $1.03
- Analyst Decision
- JMM
- CTSO Strong Buy
- Analyst Count
- JMM 0
- CTSO 3
- Target Price
- JMM N/A
- CTSO $4.67
- AVG Volume (30 Days)
- JMM 16.1K
- CTSO 538.8K
- Earning Date
- JMM 01-01-0001
- CTSO 03-06-2025
- Dividend Yield
- JMM 5.44%
- CTSO N/A
- EPS Growth
- JMM N/A
- CTSO N/A
- EPS
- JMM N/A
- CTSO N/A
- Revenue
- JMM N/A
- CTSO $37,739,531.00
- Revenue This Year
- JMM N/A
- CTSO $9.20
- Revenue Next Year
- JMM N/A
- CTSO $11.64
- P/E Ratio
- JMM N/A
- CTSO N/A
- Revenue Growth
- JMM N/A
- CTSO 1.80
- 52 Week Low
- JMM $5.29
- CTSO $0.70
- 52 Week High
- JMM $6.10
- CTSO $1.59
- Technical
- Relative Strength Index (RSI)
- JMM 43.26
- CTSO 55.82
- Support Level
- JMM $5.97
- CTSO $1.00
- Resistance Level
- JMM $6.14
- CTSO $1.14
- Average True Range (ATR)
- JMM 0.08
- CTSO 0.09
- MACD
- JMM -0.00
- CTSO 0.01
- Stochastic Oscillator
- JMM 30.43
- CTSO 64.40
About JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities including, but not limited to residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.